UBS Raises Price Target on Accretive Health (AH); Wheeling and Dealing Removes Substantial Overhang
Tweet Send to a Friend
UBS maintains a 'Neutral' on Accretive Health (NYSE: AH) price target of $12.00 (from $11.00).
Analyst, Stephen Shankman, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Stephen Shankman, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
